Survival Benefits of Metformin for Colorectal Cancer Patients with Diabetes: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Several studies suggest that metformin has the potential effect of reducing cancer risk. However, its survival benefit in patients with colorectal cancer (CRC) and diabetes is unknown. The aim of our study is to address the effect of metformin on outcomes for CRC based on a systematic review and meta-analysis. METHODS AND FINDINGS: We searched EMBASE and MEDLINE databases from inception through August, 2013, using search terms related to metformin, diabetes, colorectal cancer, and prognostic outcome. The outcome measures were hazard ratios (HRs) with 95% CIs comparing CRC survival in diabetic patients using metformin and without using metformin. The primary end points were overall survival (OS) and CRC specific survival (CS). A total of six cohort studies including 2,461 patients met full eligibility criteria. The pooled HR favoring metformin users was 0.56 for OS (95% CI, 0.41 to 0.77) and 0.66 for CRC-specific survival (95% CI, 0.50 to 0.87). Thus metformin therapy reduced the risk of all cause of death by 44% and the risk of CRC specific death by 34% in CRC patients compared to those in non-users. However, evidence of heterogeneity and possible publication bias was noted for OS. CONCLUSIONS: Patients with CRC and diabetes treated with metformin appear to have an improved survival outcome. Prospective study should be warranted to examine the association between metformin exposure intensity as well as some other confounding variables and survival outcome in diabetic CRC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61602-x · Cited by 21,320
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · Preventive Medicine · doi:10.1016/j.ypmed.2007.08.012 · Cited by 2,698
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · Epidemiology · doi:10.1097/ede.0b013e3181577654 · Cited by 1,991
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124
Diabetes Mellitus and Risk of Colorectal Cancer: A Meta-Analysis
Larsson, S. C., Orsini, N., & Wolk, A. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji375 · Cited by 1,038 · cited 1×
“Previous metaanalyses have demonstrated that type 2 diabetes is associated with increased risk of CRC [25,26] and metformin is a commonly prescribed anti-diabetic agent in outpatients.”
BackgroundNew Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996
Barone, B. B. (2008) · JAMA · doi:10.1001/jama.2008.824 · Cited by 881 · cited 3×
“STROBE checklist was applied for quality assessment in cohort studies concerning some of important factors recommended previously by Elm et al and Barone et al [10,14].”
BackgroundMethodInoue, M. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1871 · Cited by 561
Cited by
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
Coyle, C., Cafferty, F. H., Vale, C., & Langley, R. E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw410 · Cited by 452
Tang, G. H., Satkunam, M., Pond, G. R., Steinberg, G. R., Blandino, G., Schünemann, H. J., & Muti, P. (2018) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0936 · Cited by 117
“The activation of AMPK has been shown to inhibit the mTOR signaling pathway, which is known to promote cell growth and tumorigenesis (7, 17, 18, 71, 72).”
BackgroundMetformin use and the risk of colorectal adenoma: A systematic review and meta-analysis
Jung, Y. S., Park, C. H., Eun, C. S., Park, D. I., & Han, D. S. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13639 · Cited by 49
Perez-Lopez, F. R., Pasupuleti, V., Gianuzzi, X., Palma-Ardiles, G., Hernandez-Fernandez, W., & Hernandez, A. V. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.04.001 · Cited by 45
Du, L., Wang, M., Kang, Y., Li, B., Guo, M., Cheng, Z., & Bi, C. (2017) · Oncotarget · doi:10.18632/oncotarget.14688 · Cited by 32
“Several meta-analyses have also examined the association between metformin and CRC survival [20, 21].”
Background
Metadata
- Authors
- Mei, Z.-B., Zhang, Z.-J., Liu, C.-Y., Liu, Y., Cui, A., Liang, Z.-L., Wang, G.-H., & Cui, L.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-03-19
- Volume
- 9
- Issue
- 3
- Pages
- e91818
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2063130014
- Cited by
- 89
- References
- 11
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survival Benefits of Metformin for Colorectal Cancer Patients with Diabetes: A Systematic Review and Meta-Analysis. https://app.cochat.ai/papers/10.1371/journal.pone.0091818
- The paper
- Mei, Z.-B., Zhang, Z.-J., Liu, C.-Y., Liu, Y., Cui, A., Liang, Z.-L., Wang, G.-H., & Cui, L. (2014). Survival Benefits of Metformin for Colorectal Cancer Patients with Diabetes: A Systematic Review and Meta-Analysis. PLoS ONE. https://doi.org/10.1371/journal.pone.0091818
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.